Design Therapeutics (DSGN) Short-term Investments (2020 - 2026)

Design Therapeutics has disclosed Short-term Investments across 7 years of filings, most recently posting $210.1 million for Q1 2026.

• Short-term Investments for Q1 2026 came in at $210.1 million, down 2.76% year-over-year; the trailing twelve-month figure through Mar 2026 was $210.1 million (down 2.76% YoY), and the FY2025 annual result was $203.0 million, down 8.94% from the prior year.
• Short-term Investments came in at $210.1 million for Q1 2026 at Design Therapeutics, up from $203.0 million in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $303.9 million in Q4 2022 to a low of $83.9 million in Q1 2022.
• The 5-year median for Short-term Investments is $223.7 million (2024), against an average of $231.5 million.
• Across the five-year window, Short-term Investments soared 290011.54% in 2022 and fell 21.96% in 2024, its largest moves.
• Design Therapeutics' Short-term Investments stood at $303.9 million in 2022, then slipped by 14.25% to $260.6 million in 2023, then retreated by 14.46% to $222.9 million in 2024, then declined by 8.94% to $203.0 million in 2025, then gained by 3.48% to $210.1 million in 2026.
• The last three Short-term Investments figures came in at $210.1 million (Q1 2026), $203.0 million (Q4 2025), and $190.9 million (Q3 2025), per Business Quant data.